Tilray Brands (TLRY) Cash & Equivalents (2017 - 2026)
Tilray Brands' (TLRY) quarterly Cash & Equivalents came in at $229.3 million in Q2 2026, up 3.46% YoY from $221.7 million in Q2 2025, and up 12.08% on a QoQ basis from $204.6 million in Q1 2026.
Tilray Brands (TLRY) Cash & Equivalents (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Cash & Equivalents data on file, last reported at $229.3 million in Q2 2026.
- Quarterly Cash & Equivalents rose 3.46% year-over-year to $229.3 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $229.3 million (up 3.46% YoY) and the FY2026 annual result came in at $229.3 million, up 3.46% from the prior year.
- Cash & Equivalents rose to $229.3 million in Q2 2026, from $204.6 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $490.6 million in Q3 2022 to a low of $143.4 million in Q4 2023.
- A 5-year average of $235.6 million and a median of $206.6 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents sank 63.82% — and 2024, when it jumped 32.31%.
- Tracing TLRY's Cash & Equivalents over 5 years: stood at $190.2 million in 2022, then declined by 24.63% to $143.4 million in 2023, then jumped by 32.31% to $189.7 million in 2024, then jumped by 30.05% to $246.7 million in 2025, then retreated by 7.04% to $229.3 million in 2026.
- The last three Cash & Equivalents figures came in at $229.3 million (Q2 2026), $204.6 million (Q1 2026), and $246.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Tilray Brands | 513.87 Mn | 279.24 Mn | 90.52 Mn | 229.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 229.34 Mn |
| Feb 28, 2026 | 204.62 Mn |
| Nov 30, 2025 | 246.70 Mn |
| Aug 31, 2025 | 264.83 Mn |
| May 31, 2025 | 221.67 Mn |
| Nov 30, 2024 | 189.70 Mn |
| Aug 31, 2024 | 205.19 Mn |
| May 31, 2024 | 228.34 Mn |
| Feb 29, 2024 | 146.25 Mn |
| Nov 30, 2023 | 143.37 Mn |
| Aug 31, 2023 | 177.52 Mn |
| May 31, 2023 | 206.63 Mn |
| Feb 28, 2023 | 165.00 Mn |
| Nov 30, 2022 | 190.22 Mn |
| Aug 31, 2022 | 490.64 Mn |
| May 31, 2022 | 415.91 Mn |
| Feb 28, 2022 | 279.21 Mn |
| Nov 30, 2021 | 331.78 Mn |
| Aug 31, 2021 | 376.30 Mn |
| May 31, 2021 | 488.47 Mn |